A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, intermediate, low, low-dose-rate, monotherapy, outcome, risk, seeds | 3 Comments »
As some of us have long suspected and understood, using data from men treated 20+ years ago as a guide to what would happen if you were treated the same way today is not really a very good idea. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: comparison, outcome, today, Treatment, yesterday | 3 Comments »
A large, well-done, confirmed, randomized clinical trial (RCT) is the only evidence that proves that one therapy is better than other. According to current consensus, this is deemed “Level 1a” evidence. But this high level of evidence is seldom available. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: decision-making, dose, outcome, radiation, risk, salvage | 2 Comments »
A newly published report in The Lancet Oncology has pretty much finally confirmed what many of us have been assuming for a long time now: … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: laparoscopic, open, outcome, prostatectomy, radical, robot-assisted | 1 Comment »
According to a presentation given last week in San Francisco, lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy has significant clinical activity in men with metastatic prostate cancer (as opposed to just in men with very late stages of prostate cancer). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, lutetium, lutetium-177, outcome, radioligand | 11 Comments »
We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, outcome, photodynamic, surveillance, targeted, TOOKAD, vascular, VTP | 3 Comments »
In the first trial ever to randomly assign patients to extreme hypofractionation, primary radiation therapy delivered in just seven treatments had the same effectiveness and safety as 39 treatments. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: 3D-CRT, body, conventional, outcome, radiation, randomized, SBRT, stereotactic, trial | 2 Comments »
A presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data on outcomes of men initially managed on active surveillance at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York over the past 17 years. … READ MORE…
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, outcome, protocol, rigor, risk, surveillance | 2 Comments »
In October last year we had expressed the hope that data from the Men’s Eating and Living (MEAL) study would be presented at a major medical meeting this year. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, outcome, surveillance, trial | Leave a comment »
One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: ac tive, ADT, leuprolide, low risk, outcome, short-term, surveillance, trial | 9 Comments »
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen, deprivation, mitoxantrone, outcome, prednisone, survival | 3 Comments »
A new article in this week’s New England Journal of Medicine has just reported the full results of the so-called PRECISION trial of MRI-targeted vs. standard biopsy techniques in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, outcome, standard, targeted | 5 Comments »
Last week, we saw that escalated dose did not improve 10-year overall survival in high-risk men (see this link). The latest published findings of the randomized clinical trial (RTOG 0126) prove that 8-year overall survival was not improved in intermediate-risk men who received a higher radiation dose. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: intermediate, outcome, radiation, risk, survival, therapy | 3 Comments »
